XJPX
4694
Market cap849mUSD
Oct 09, Last price
3,650.00JPY
1D
1.96%
1Q
-0.14%
Jan 2017
31.01%
IPO
86.22%
Name
BML Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BML, Inc. is a Japanese corporation specializing in a comprehensive range of laboratory diagnostics and related services. The company conducts standard analyses such as biochemical and hematological screenings, in addition to advanced specialized tests including radioimmunoassay (RIA), cellular diagnostics, immunology, and DNA analysis. It also provides microbiological assessments for medical and pharmaceutical organizations, along with diagnostic services covering critical areas like oncology, infectious diseases, metabolic disorders (diabetes, hypertension), allergies, and genetic studies. To optimize laboratory operations, BML develops proprietary automation systems, Frontier and Symphony, designed to streamline processes from initial sample sorting and dispensing through to subsequent testing. The firm also supports medical information networking via electronic health records and offers preventative healthcare solutions. BML's extensive service portfolio includes food safety and environmental health. Its food division provides comprehensive hygiene control and processing support, encompassing contractual microbiological testing for raw ingredients, prepared, and processed foods. This extends to environmental hygiene assessments for food facilities and kitchens, general microorganism testing, and the evaluation of genetically modified organisms. Environmental services comprise drinking water and wastewater analysis, occupational health management (measuring airborne substances like ethylene oxide, formaldehyde, organic solvents, and dust), comprehensive indoor environmental monitoring (identifying contaminants and other variables), and biological dioxin surveillance. Moreover, BML performs analyses for residual agricultural chemicals, offers dental diagnostics for caries and periodontal diseases, provides consulting for pharmaceutical product approvals, conducts investigative analyses for drug manufacturers, and performs gene expression analysis, specifically identifying genes linked to infectious disease susceptibility. Founded in 1955, BML, Inc. is headquartered in Tokyo, Japan.
Key people
Hiroyuki Kigoshi
Managing Executive Officer · since 2022
Masami Kondo
Managing Executive Officer, Chief Director of In-Hospital Inspection, Director of 2nd In-Hospital Inspection · since 2025
Michihiro Aono
Executive Officer, Director of Reliability Assurance · since 2020
Satoshi Enomoto
Executive Officer · since 2021
Hiromi Nakahara
Executive Officer, Director of Risk Administration · since 2021
Yutaka Sakamaki
Executive Officer, Director of General Affairs · since 2022
Katsuaki Takei
Executive Officer, Deputy Chief Director of BML Inspection, Director of Bacteriological Testing, Director of Reagent · since 2025
Koji Uno
Executive Officer, Director of Group Planning in Main Planning Unit, Manager of DX Promotion Office, Manager of Overseas Business Office · since 2025
Kazuhiro Yamashita
Executive Officer, Director of Electronic Chart · since 2023
Yuji Yamashita
Executive Officer, Chief Director of System, Director · since 2022
Toshihiro Yanoma
Executive Officer, Director of Medical Information System Sales · since 2023
Nobuki Arai
Vice President, Chief Director of Advanced Technology Development, Director of BML Research Institute, Representative Director · since 2025
Kensuke Kondo
President, Executive Officer, Chairman of Subsidiaries, Representative Director · since 2023
Hideaki Osawa
Executive Officer, Chief Director of Sales, Director of Proposal Sales, Director of Pharmaceutical Clinical Trial Sales, Director · since 2023
Kenji Shibata
Executive Officer, Chief Director of BML Inspection, Director of 4th Research Institute Inspection, Director · since 2025
Norihisa Takebe
Senior Managing Executive Officer, Chief Director of Planning, Director · since 2024
Tatsuharu Arai
Independent Director · since 2021
Independent Director · since 2025
Shigeru Osawa
Independent Director · since 2022
Yukiko Yoritaka
Independent Director · since 2020
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||